Steve Clark

Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.
Pain Therapeutics, Inc. (NASDAQ:PTIE)

Pain Therapeutics, Inc. (NASDAQ:PTIE) Announces Positive Results

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Austin, TX-based Pain Therapeutics, Inc. (NASDAQ:PTIE) shares are up over 35% in mid-day trading after the firm announced the completion of a Phase I clinical study for PTI-125, a new experimental drug therapy to treat Alzheimer’s Disease. By 1PM, PTIE shares had a volume of over 16.7 million for a stock that has an average daily trading volume of less than 40,000 shares.

Pain Therapeutics, Inc. (NASDAQ:PTIE)

Remi Barbier, President & CEO of Pain Therapeutics, Inc. (NASDAQ:PTIE) stated “The clinical data are encouraging. Given the absence of dose-limiting effects in healthy adults, an excellent non-clinical safety database, a strong scientific rationale, and multiple peer-reviewed publications and research grant awards, we are eager to move this drug program to the next level of development.”

Study Results

Pain Therapeutics conducted this study with support from a $1.7 million research grant award from the National Institute on Aging, part of the National Institutes of Health.

PTI-125 was evaluated, at a single U.S. site, in 24 healthy human volunteers for safety, tolerability, and pharmacokinetics. The drug was well-tolerated in all subjects.  Importantly, PTI-125 showed no treatment-related adverse effects and no dose-limiting safety findings.  Pharmacokinetic measurements showed PTI-125, a small molecule, was rapidly absorbed.  Dose-proportionality outcomes were observed over the entire dose range of 50 to 200 mg.  Pain Therapeutics Inc. (NASDAQ”PTIE) scientists plan to present full results of this study at the 10th Annual International Conference on Clinical Trials on Alzheimer’s Disease (CTAD), in Boston, MA, on November 1-4th.

PTIE Stock Performance

Pain Therapeutics, Inc. (NASDAQ:PTIE) is a nano-cap company and has a market capitalization less than $30 million. The biotechnology company has been without sales for the last three years and, accordingly, has posted per share losses over that time period (-$1.92), (-$2.16), and for 2016 (-$2.26). On a positive note, the number of outstanding shares has not materially increased over the past five years so equity dilution has been of little concern.

 

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $PTIE and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Top Image Systems Ltd. (NASDAQ:TISA)

Top Image Systems Ltd. (NASDAQ:TISA) Unveils eFLOW AP

Top Image Systems Ltd. (NASDAQ:TISA)

Top Image Systems Ltd. (NASDAQ:TISA) traded lower after unveiling a cloud-based eFLOW AP solution for enhancing automated invoice processing. Shares of the global provider of solutions for facilitating digital business fell 7.36% to end Monday’s trading session at $1.51.

Top Image Systems Ltd. (NASDAQ:TISA)

eFLOW AP Solution

The sell-off came as a surprise given that the stock has been on an impressive run since the start of the month. Top Image Systems Ltd. (NASDAQ:TISA) is up by more than 20% for the month and full year, as it continues to trade in an uptrend.

Top Image Systems is a global innovator of on-premise and cloud based applications that seek to optimize content-driven business processes. The eFLOW AP solution is one of the company’s lead solutions designed to empower a wide range of accounts payable functionalities with end-to-end automated invoice processing.

The solution can capture, recognize, and extract invoice data from the cloud and match it with incoming data against SAP Business One Master data. According to the company’s Chief Executive Officer Brendan Reidy, the launch of the new cloud AP solution should position the company for accelerated growth in cloud applications.

“Integrating with SAP Business One further strengthens our footprint in the SAP market segment. Our cloud solution supports a multi-tier software strategy for SAP customers with SAP ECC deployed at the enterprise level and SAP Business One utilized in subsidiaries,” said Brendan Reidy, CEO of Top Image Systems.

Southeast Asia Expansion

Separately, a top financial service group in Southeast Asia has selected Top Image Systems Ltd. (NASDAQ:TISA) to implement an automated Trade Finance document processing solution. The organization, which boast of over 500 branches, receives, on a daily basis, approximately 10,000 documents through various channels.

The automated Trade Finance processing solution is designed to automate the capture recognition and classification of incoming documents. It also utilizes advanced machine learning technology to process a wide range of document templates and transfer text and handwritten content.

According to Mr. Reidy, the contract underscores the traction that Top Image Systems Ltd. (NASDAQ:TISA) is receiving in Asia Pacific Region.

“Banking and financial services represent a significant contribution to our overall revenue mix globally. We are poised to capitalize on the increased investments that banks and financial services organizations are making to automate highly labor-intensive processes in order to reduce transaction costs and improve customer service levels,” said Mr. Reidy.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $TISA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) Stock Making New Run

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Shares of Kalvista Pharmaceuticals Inc (NASDAQ:KALV) have rallied two days in a row on heavy volume two weeks after reaching a new 52-week high on news of a collaboration with Merck. On October 10, 2017 Kalvista announced Merck acquired around a 10% stake for a payment of $9.1 million. That news sent the shares rocketing over 38% and establishing a new 52-week high at $15.80, but profit-takers stepped in and the shares closed just over $10. Shares traded sideways over the next eight trading days, then yesterday shares spiked again and then gapped up to open today before hitting an inter-day high of $14.46, and closing at $13.02.

Kalvista Pharmaceuticals Inc (NASDAQ:KALV)

Deal Terms

The collaboration between Merck and Kalvista Pharmaceuticals Inc (NASDAQ:KALV) for KVD001, the Kalvista’s investigational intravitreal injection candidate currently in development for potential treatment of diabetic macular edema (DME), as well as future oral DME compounds based upon plasma kallikrein inhibition. Under the terms of the agreement, KalVista has granted to Merck certain rights including an option to acquire KVD001 through a period following completion of the Phase 2 proof-of-concept trial that KalVista intends to commence later this year. Kalvista Pharmaceuticals Inc (NASDAQ:KALV) has also granted to Merck a similar option to acquire investigational orally delivered molecules for DME that KalVista will continue to develop as part of its ongoing research and development activities.

KALV Stock Review

Kalvista Pharmaceuticals Inc (NASDAQ:KALV) shareholders have had a good year and seen their shares appreciate by over 67% and over the past month KALV shares have gone up by over 62%. Kalvista reported no sales in 2015 or 2016 but for FY2017 they posted $1.5 million in sales. Their performance also jumped in the per share P&L. In 2016, the company posted its largest per share loss ever (-$18.23) but they shrank that number to a loss of (-$4.00) for FY2017. KALV shares have a Relative Strength Index figure of 79 – well into the “overbought” range.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $KALV and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Third Time the Charm for One Horizon Group Inc (NASDAQ:OHGI)?

One Horizon Group Inc (NASDAQ:OHGI)

One Horizon Group Inc (NASDAQ:OHGI) shares are making their third run, since the beginning of September, to close above $1.25. On Friday, OHGI shares closed at $1.00, and quickly rose to an inter-day high of $1.34 on heavy volume before falling back to below $1.20 with 3.5 hours left in the trading day.

One Horizon Group Inc (NASDAQ:OHGI)

One Horizon Group Business

London, England-based One Horizon Group Inc (NASDAQ:OHGI) develops and licenses, globally, software for mobile voice over Internet protocol (VoIP). The company develops Horizon Platform, used to compete against the over the top provider’s applications that are running on their networks; and Horizon Call, a mobile application, which enables bandwidth-efficient VoIP calls over a smartphone. It offers retail smartphone VoIP, messaging, and advertising service under the Aishuo brand name; and software maintenance services.

One Horizon Group Inc (NASDAQ:OHGI) has a market capitalization of under $11 million. Last year it reported $1.6 million in sales which was better than 2015’s figure of $1.5 million, but far under the 2014 sales figure of $5.1 million. Worryingly, the company has a published “cash per share” figure of only $0.03.

OHGI Stock

OHGI stock is up over 40% for the quarter but is down for the year by almost 45%. However the stock is well off its 52-week low of $0.57 but around 60% below its 52-week high of $3.12. One Horizon Group Inc (NASDAQ:OHGI) cut its 2015 per share loss of (-$1.12) to (-$0.95) for 2016. Fortunately for investors, the company has been fairly steady regarding its number of outstanding shares so dilution has not been too much of an issue. Will the buying strength hold and allow the momentum to continue? The stock has a relative strength Index figure of over 71 – typically a number over 70 triggers an “overbought” status among traders.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OHGI and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) Expanding Into Agriculture

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ)

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) shares gained 43.9% after the independent energy company announced it had entered into a merger definitive agreement with AgEagle Aerial Systems. The merger will expand the company’s footprint into the commercial agriculture drone business.

AgEagle boasts a product portfolio designed to help improve farming techniques with GPS technology and high-resolution aerial imagery. The precision agriculture sector presents unique growth opportunities given that there are more than 2.1 million farms that the combined company will be able to target.

“Our goal at EnerJex has been to maximize stockholder value and we believe AgEagle, with its strong leadership team, is well-positioned to capitalize on the fast-growing agriculture drone market,” said Louis Schott, CEO of EnerJex. “While AgEagle is focused on the agriculture market, we believe there is opportunity for drones in the oil and gas.

Investor’s reaction to the proposed merger has been positive seen by the stock breaking a key resistance level after consolodating for the better part of the year. The stock is now up by more than 30% for the year.

Merger Agreement

Under the terms of the merger agreement, EnerJex Resources Inc. (NYSEAMERICAN:ENRJ)’s Series A preferred shareholders are to own approximately 15% of the combined company. The transaction values AgEagle at $20 million prior to any financing. Each company’s board of directors have approved the proposed merger, which is set to be finalized in the fourth quarter.

However, shareholders of both EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) and AgEagle must approve the transaction before it is consummated. Other closing conditions include the raising of at least $4 million, and approval by the NYSE for the listing of the combined company’s common stock.

EnerJex has announced plans to divest its principal assets including its Kansas oil and gas properties in anticipation of the merger.

Non-Compliance Notice

Separately, EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) has received a notice of non-compliance from the NASDAQ Capital Market. The notice raises concerns about the stockholder’s equity which has fallen below the minimum $2 million requirements. The share price is another concern – it has dropped below the $1 a share bid requirement

EnerJex Resources Inc. (NYSEAMERICAN:ENRJ) has since been given until November 19, 2017, to file a detailed plan on how it plans to regain compliance before April 19, 2019.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $ENRJ and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Concordia International Corp (NASDAQ:CXRX) $2 Billion Debt Reduction Plan

Concordia International Corp (NASDAQ:CXRX)

Concordia International Corp (NASDAQ:CXRX) fell 38.7% after announcing it was taking steps to realign its capital structure. Part of the plan involves reducing existing secured and unsecured debt obligations. The company also plans to significantly reduce its annual interest expense.

Concordia International Corp (NASDAQ:CXRX)

CXRX Investor Reaction

The specialty Pharmaceutical Company has already effected a 30-day grace period to defer the payment of about $26 million of interest on its $735 million unsecured notes. Investors continue to push the stock lower even as the company moves to align its capital structure.

The stock is already down by more than 70% for the year, a sell-off that has pushed it below the $1 a share mark. Concordia International Corp (NASDAQ:CXRX) is now at risk of being delisted from the NASDAQ Capital Market as it does not meet the minimum $1 a share bid requirement.

However, the Chief Executive Officer, Allan Oberman, remains upbeat about the company’s long-term growth following the proposed recapitalization transaction. The executive expects the transaction to significantly reduce the company’s outstanding debt and annual interest cost.

“The decision to use the CBCA process to achieve our financial goals was a strategic one that we believe will protect our business, preserve our cash, and give us extra time to negotiate with lenders to ensure we achieve the best possible transaction for our Company, employees, suppliers, customers and other business partners,” said Mr. Oberman.

Recapitalization Transaction

The proposed recapitalization that Concordia International Corp (NASDAQ:CXRX) intends to implement will reduce the company’s existing debt obligations by about $2 billion. However, it may also result in diluting shareholder equity.

Concordia is currently in discussions with its lenders and advisors as it seeks to finalize the terms of the proposed transactions. The company has also obtained an interim order from the Ontario Superior Court of Justice which granted an interim stay of proceedings and protects it from any defaults.

The company had a total of $340 million in cash on hand as of the end of September 30, 2017, which is sufficient to meet financial obligations related to employees, suppliers, and customers. Concordia International Corp (NASDAQ:CXRX) is an international specialty pharmaceutical company with over 200 patented products. It operates in more than 90 countries.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $CXRX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Rennova Health Inc. (NASDAQ:RNVA) Revenue Stream Strengthened

Rennova Health Inc. (NASDAQ:RNVA)

Rennova Health Inc. (NASDAQ:RNVA) shares fell 20.2% after the company announced its Big South Medical Center had been granted a three-year certificate of accreditation by the Center for Medicare and Medicaid Services. According to the Chief Executive officer, Seamus Lagan, the certification paves way for the company to start receiving payments for services rendered.

Rennova Health Inc. (NASDAQ:RNVA)

CMS Accreditation

The certification and opening of the Big South Medical Center signify a new direction to Rennova Health Inc. (NASDAQ:RNVA) and is expected to lead to a reliable revenue stream. The hospital had unaudited annual revenues of $12 million and EBITDA OF $1.3 million in 2015.

Rennova has been a shadow of itself in the stock market. The stock is down by more than 90% for the year after dropping from $44 a share to current $0.98 trading level.

Rennova Health Inc. (NASDAQ:RNVA) is an integrated provider of diagnostic and supportive software solutions through its medical centers. Approximately 60% of the services that the company provides are payable through federal payers.

Some of the services offered by Big South Fork Medical Center include 24/7 emergency services as well as radiology services and X-ray CT scan and ultrasound. Rennova remains optimistic of being able to rebuild Big South Medical Center revenues to levels achieved in 2015, based on the hospital first month of operations.

“Receiving our Medicare number is the final hurdle that will enable us to collect payment for services provided. We look forward to the continued success and growth of this hospital and remain confident that this is an excellent business model to create value for our shareholders,” said CEO Seamus Lagan.

Cigna Suit Win

Separately, Rennova Health Inc. (NASDAQ:RNVA) has won an appeal in an Eleventh Circuit Court of Appeals in a long-running CIGNA Lawsuit. The company’s subsidiaries Bio health Medical Laboratory and PB Laboratories had filed a lawsuit against CIGNA in 2015 accusing the company of failing to pay for laboratories services offered.

A U.S District Court dismissed the laboratory’s claims for lack of standing. The subsidiaries appealed the ruling to the Eleventh Circuit Court of Appeals which on its part found the companies have the standing to raise claims.

“This is an exciting development for us and allows us to push forward in our pursuit of the total amount of our original claims,” said Mr. Lagan.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $RNVA and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences, Inc. (NASDAQ:SSKN) Partners with MedResults Network

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

Strata Skin Sciences, Inc. (NASDAQ:SSKN) fell 3.43% after announcing the signing of an agreement with MedResults Network (MRN) which they hope will greatly benefit the company’s sales efforts in the aesthetics market.

Strata Skin Sciences, Inc. (NASDAQ:SSKN)

MRN Marketing Deal

MRN is to assist Strata Skin Sciences, Inc. (NASDAQ:SSKN) on the marketing of products for various dermatologic conditions. The Group Purchasing Organization has more than 3,000 members and dermatology offices that should be of great help in enhancing sales efforts in the industry.

“STRATA’s Aesthetic products, Nordlys and STRATAPEN, are excellent products that are in growing sectors of the Aesthetic market. MRN’s mission is to offer our members best-in-class products from world-class companies,” said MRN President, Jeff Routledge.

SSKN Stock Performance

Strata Skin had initially popped to highs of $2.70 a share on the announcement of a strategic alliance, before dropping to end Wednesday’s trading session at $1.69 a share. The stock continues to trade in a downtrend, after coming under pressure on rising to $5 a share in April.

Despite the recent sell-off in the stock, HC Wainwright & Co analyst, Joseph Pantginis, remains bullish about the medical technology company prospects. The analyst has a ‘buy’ rating on the stock with a share price target of $12.

According to the analyst, a deal with MedResults which has, more than 3,000 members could serve as an important marketing platform. Pantginis expects the deal to increase the visibility of Strata’s skin products which should lead to more sales.

Debt Settlement

Separately, Strata Skin Sciences, Inc. (NASDAQ:SSKN) recently closed a transaction with holders for its 2.25% Senior Series A Secured Convertible Debentures and 4% Senior Secured Convertible Debentures, both due July 30, 2021. The holders agreed to exchange all the debentures with a principal amount of $40.7 million for 40,617 newly created Series C shares.

The transaction eliminated Strata Skin Sciences, Inc. (NASDAQ:SSKN) senior secured debt and obligation to pay $4 million of interest payments over the next four years.

“The interest savings will also provide flexibility to carry out our strategic plan for external and organic growth. [..] Furthermore, the reduction in debt will result in a simplified balance sheet. We believe this will improve our access to the capital markets and increase our financial flexibility,” said Mr. McCaney.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $SSKN and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Inpixon (NASDAQ:INPX)

Is Inpixon (NASDAQ:INPX) Showing Signs of Life?

Inpixon (NASDAQ:INPX)

After losing over 88% of their value over the previous year, traders are wondering if they are seeing signs of life in shares of Inpixon (NASDAQ:INPX). Yesterday INPX shares closed at $0.39, then briefly shot up to break through the $0.50 level before sliding back to end the day at $0.44. Volume for the software company was about four times its daily average.

Inpixon (NASDAQ:INPX)

Palo Alto, CA-based Inpixon (NASDAQ:INPX) provides, globally, data analytics services to commercial entities and governments. It offers AirPatrol, a location-based security and marketing platform for wireless and cellular devices to detect, monitor, and manage the content and behavior of smartphones, tablets, and other mobile. The company also provides enterprise computing and storage, virtualization, business continuity, networking, and information technology business consulting services.

INPX Stock

While the technology company has posted an impressive month in which it has gained over 91%, issues continue to worry investors. To begin with, share dilution has been an annual problem. In 2013 there were 820,000 outstanding shares. That number has increased every year and in 2016 the number of outstanding shares was 1.74 million – more than double their 2013 figure. Still, from 2013 to 2015, Inpixon (NASDAQ:INPX) had increasing year-on-year sales. For 2013, sales were at $50.6 million and in 2015 the reported sales were $67 million. But in 2016, sales fell to $53.29 million.

Earnings have been in a downward trajectory since 2012. That year there was a per share loss of (-$0.74). That per share loss increased each of the following years and in 2016 stood at (-$15.17).

Commonly used ratios are not looking good either. The company, according to recent reports, has a cash per share value of just $0.07. Further, the book value per share is -0.84. When one looks at the entirety of the shares it is not a wonder that INPX shares have fallen so far from their 52-week high of $11.08.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $INPX and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.

Ocean Power Technologies Inc (NASDAQ:OPTT)

Ocean Power Technologies Inc (NASDAQ:OPTT) Making Waves

Ocean Power Technologies Inc (NASDAQ:OPTT)

Ocean Power Technologies Inc (NASDAQ:OPTT) stock is up almost 50% in mid-day trading on the back of volumes that are over 120 times their daily average. OPTT shares closed at $1.44 yesterday and gapped up to open at $1.70 before hitting an inter-day high of $2.54. By 2:30 PM EST OPTT stock was trading around the $2 handle.

Ocean Power Technologies Inc (NASDAQ:OPTT)

About Ocean Power Technologies

Ocean Power Technologies (Nasdaq:OPTT) is a develops renewable wave-energy technology that converts ocean wave energy into electricity. The company’s proprietary PowerBuoy® technology is based on a modular design and has undergone periodic ocean testing since 1997. The PowerBuoy system integrates patented technologies in hydrodynamics, electronics, energy conversion, and computer control systems to extract the natural energy in ocean waves. The result is a leading edge, ocean-tested, proprietary autonomous system that reportedly turns wave power into reliable, clean, and environmentally beneficial electricity for offshore applications.

OPTT shares have a daily average volume of just over 450,000. However, at the time of this writing, over 36.7 million shares had traded hands. Prior to today’s trading, over the past year, shares have lost close to 60% of their value and been trading under $2 – well off their 52-week high of $5.89. However, OPTT stock has done well over the past month as it has gained over 12%.

OPTT Stock

Ocean Power Technologies (Nasdaq:OPTT) shareholders have had their equity diluted over the past few years. In 2013, the number of outstanding shares was listed at 1.03 million. The company has reported that there are 4.26 million shares outstanding at this time. Sales have also been weak. In 2015, sales were reported at $4.1 million but by 2017 the reported sales were just $800,000. However, per share losses have been contracting on an annual basis. In 2013, the company posted a per share loss of $14.25. That loss shrank each year thereafter and was just (-$2.23) for FY2017.

I have no positions in any of the stocks mentioned, and have no plans to initiate any positions within the next 72 hours. All information, including any data, is provided without any guarantees of accuracy.

Don’t miss out! Stay informed on $OPTT and receive breaking news on other hot stocks by signing up for our free newsletter!

About the author: Steve Clark is a 23-year Wall St professional with stints in M&A, risk management, and algorithm trading. Steve keeps his head in the game by looking for, and writing about, small companies that often get overlooked by the big investment firms.